XNASMNOV
Market cap96mUSD
Jan 10, Last price
1.96USD
1D
-1.51%
1Q
10.11%
Jan 2017
-67.50%
IPO
-83.80%
Name
MediciNova Inc
Chart & Performance
P/E
—
P/S
96.13
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
3.59%
Rev. gr., 5y
%
Revenues
1m
Net income
-9m
L-39.08%
CFO
-7m
L-42.45%
Earnings
Feb 13, 2025
Profile
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 1,000 | ||||||||
Cost of revenue | 10,900 | 14,841 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (9,900) | (14,841) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 3 | 3 | |||||||
Tax Rate | |||||||||
NOPAT | (9,903) | (14,844) | |||||||
Net income | (8,572) -39.08% | (14,069) 38.83% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 8 | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 216 | 158 | |||||||
Long-term debt | 216 | 681 | |||||||
Deferred revenue | (524) | ||||||||
Other long-term liabilities | 411 | 524 | |||||||
Net debt | (50,568) | (57,649) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (7,431) | (12,912) | |||||||
CAPEX | (21) | (5) | |||||||
Cash from investing activities | 39,908 | (40,005) | |||||||
Cash from financing activities | 8 | ||||||||
FCF | (9,850) | (14,637) | |||||||
| Balance | |||||||||
Cash | 50,999 | 58,488 | |||||||
Long term investments | |||||||||
Excess cash | 50,949 | 58,488 | |||||||
Stockholders' equity | (415,771) | (407,196) | |||||||
Invested Capital | 478,776 | 478,120 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 49,046 | 49,045 | |||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (9,880) | (14,823) | |||||||
EV/EBITDA | |||||||||
Interest | 562 | ||||||||
Interest/NOPBT | |||||||||